Core Insights - Meta Platforms (META) is experiencing growth due to new features across its Family of Apps, which is expected to enhance user engagement and drive advertising revenues [1][11] Group 1: Financial Performance - In Q4 2025, Meta's advertising revenues rose by 24.3% year over year to $58.14 billion, constituting 97.1% of total quarterly revenues [1][11] - The company anticipates total revenues between $53.5 billion and $56.5 billion for Q1 2026, with a Zacks Consensus Estimate of $55.34 billion, indicating a 30.78% increase from the previous year [5] Group 2: User Engagement and Features - Meta's platforms collectively reached over 3.58 billion daily active users, with Facebook and WhatsApp exceeding two billion daily actives, and Instagram nearing two billion [2] - Instagram's Reels watch time increased by over 30% year over year, while Facebook saw a 7% rise in views of organic feed and video posts due to ranking improvements [3] - WhatsApp expanded its paid messaging capabilities, surpassing a $2 billion annual run rate, and introduced AI tools facilitating over one million weekly conversations between users and businesses [4] Group 3: Competitive Landscape - Meta faces significant competition from Snap and Reddit, both of which are enhancing their advertising capabilities to capture market share in the growing digital ad space [6] - Snap reported a 28% year-over-year increase in total active advertisers in Q4 2025, driven by improved advertising demand [7] - Reddit's advertising revenues surged by 75% year over year to $690 million in Q4 2025, supported by user-friendly features and expanded advertiser tools [8] Group 4: Stock Performance and Valuation - META's shares have declined by 25.2% over the past six months, underperforming the broader Zacks Computer & Technology sector, which fell by 7.9% [9] - The forward 12-month Price/Sales ratio for META is 5.21X, compared to 3.42X for the Internet-Software sector, indicating that META shares may be overvalued [12] - The Zacks Consensus Estimate for 2026 earnings is $29.75 per share, suggesting a year-over-year growth of 26.65% [14]

Core Viewpoint - A class action lawsuit has been filed against Coty Inc. for securities fraud, affecting shareholders who acquired stock between November 5, 2025, and February 4, 2026, with a deadline for lead plaintiff motions set for May 22, 2026 [1] Financial Performance - Coty reported second quarter fiscal 2026 results on February 5, 2026, which fell below market expectations, showing a 6% decrease in net revenue on a like-for-like basis, a 200 basis point decline in reported gross margins, and a 19% drop in adjusted operating income [3] - The company withdrew its 2026 EBITDA guidance and lowered its near-term outlook, anticipating a gross margin decline of 200 to 300 basis points and approximately breakeven EPS for Q3 [3] Management Commentary - Interim CEO Markus Strobel acknowledged the company's underperformance and emphasized the need for investment in operational effectiveness and marketing support [3] - CFO Laurent Mercier identified the Consumer Beauty segment as the main headwind affecting performance [3] Allegations in the Lawsuit - The lawsuit alleges that during the class period, Coty made materially false and misleading statements and failed to disclose adverse facts about its business, including underperformance in the Consumer Beauty segment, compressed margins due to increased marketing investments, and slowing growth in the Prestige fragrance market [4]

Core Viewpoint - A class action lawsuit has been filed against Gemini Space Station, Inc. (GEMI) for securities fraud, targeting investors who purchased shares during the IPO and within a specified class period [1][7]. Company Overview - Gemini Space Station, Inc. conducted its IPO on September 12, 2025, selling 15.2 million shares at $28.00 per share [3]. - As of the commencement of the lawsuit, Gemini's stock price had declined to $5.96 per share, representing a 78.7% decrease from the IPO price [6]. Recent Developments - On February 5, 2026, Gemini announced a corporate pivot to "Gemini 2.0," which included a 25% workforce reduction and exiting several international markets, leading to an 8.7% drop in stock price [4]. - Following the announcement of key executive departures and a 40% increase in operating expenses on February 17, 2026, the stock price fell further by 12.9% [5]. Allegations in the Lawsuit - The lawsuit alleges that during the class period, the company made materially false and misleading statements regarding its business viability and international expansion plans [7]. - It is claimed that the company overstated its financial and business prospects, which ultimately misled investors about the risks associated with its operations [7].

Core Viewpoint - A class action lawsuit has been filed against Lufax Holding Ltd. for securities fraud, affecting shareholders who acquired securities between April 7, 2023, and January 26, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that Lufax made materially false and misleading statements and failed to disclose adverse facts about its business and financial condition [5]. - Shareholders have until May 20, 2026, to file a lead plaintiff motion in the class action [1]. Group 2: Financial Disclosures - On January 27, 2025, Lufax announced plans to remove its auditor, PricewaterhouseCoopers (PwC), due to significant concerns regarding its financial disclosures, particularly for the 2022 and 2023 Annual Reports [3]. - On February 17, 2025, Lufax confirmed that its 2022 and 2023 financial reports were unreliable, revealing inaccuracies in the consolidated financial statements and restated net profit figures showing material declines [4]. Group 3: Impact on Shareholders - Following the announcement regarding the auditor's removal, Lufax's stock price dropped by $0.40, or 13.8%, closing at $2.49 per share on January 27, 2025, resulting in losses for investors [3].

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. (IBRX) for securities fraud, encouraging shareholders to inquire about their rights and potential recovery of losses [1][2]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of shareholders who acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, with a deadline for filing a lead plaintiff motion set for May 26, 2026 [1]. - The lawsuit alleges that the company's Executive Chairman, Patrick Soon-Shiong, made false claims about the lead biologic product, Anktiva, including that it "can cure and even prevent all cancer," which the FDA deemed misleading [3][4]. Group 2: Impact on Shareholders - Following the FDA's warning on March 24, 2026, ImmunityBio's stock price dropped by $1.98, or 21.12%, closing at $7.42 per share, resulting in significant losses for investors [3]. - The complaint asserts that the defendants failed to disclose material adverse facts about the company's business and operations, leading to misleading statements regarding its prospects [4].

Core Viewpoint - A class action lawsuit has been filed against Driven Brands Holdings Inc. for allegedly misleading investors about its financial condition during the specified Class Period from May 9, 2023, to February 24, 2026 [1][4]. Company Overview - Driven Brands, headquartered in Charlotte, NC, is the largest automotive services company in North America, offering services such as oil changes, maintenance, collision repair, glass repair, and car wash services through brands like Meineke, Maaco, and Take 5 Oil Change [3]. Legal Allegations - The lawsuit claims that Driven Brands misled investors regarding its financial health, particularly by overstating revenue and cash in previous financial statements, which necessitated restatement [4]. - On February 25, 2026, Driven Brands announced a delay in filing its annual report on Form 10-K for fiscal year 2025 due to "material errors in previously issued financial statements" dating back to 2023 [4]. Market Reaction - Following the disclosure of the financial misstatements, Driven Brands' share price fell nearly 40% [5].

Group 1 - Progress Software Corporation reported quarterly earnings of $1.60 per share, exceeding the analyst consensus estimate of $1.57 per share [1] - The company achieved quarterly sales of $247.799 million, surpassing the analyst consensus estimate of $246.401 million [1] Group 2 - Progress Software raised its FY2026 adjusted EPS guidance from a range of $5.82-$5.96 to $5.91-$6.03 and increased sales guidance from $986 million-$1 billion to $988 million-$1 billion [2] - Following the earnings announcement, Progress Software shares dipped 6.6% to trade at $26.38 [2] Group 3 - Oppenheimer analyst Ittai Kidron maintained an Outperform rating on Progress Software but lowered the price target from $70 to $57 [3] - Wedbush analyst Dan Ives also maintained an Outperform rating while cutting the price target from $65 to $45 [3] - Jefferies analyst Brent Thill maintained a Hold rating and reduced the price target from $45 to $34 [3]

Group 1 - Ariel Focus Fund reported a decline of -0.50% in Q4 2025, underperforming the S&P 500 and Russell 1000 Value indices, which gained +2.66% and +3.81% respectively, but achieved a +20.97% return over the full year [1] - The U.S. market environment in Q4 2025 was characterized by easing inflation, stable corporate earnings, and optimism around accommodative monetary policy, alongside strength in AI and cloud-driven technology stocks [1] - The fund maintained a disciplined, long-term investment approach, selectively adding to positions without making exits during the quarter [1] Group 2 - Johnson & Johnson (NYSE: JNJ) experienced a one-month return of -1.73%, with shares trading between $141.50 and $251.71 over the last 52 weeks, closing at approximately $242.49 on March 30, 2026, with a market capitalization of about $584.38 billion [2] - Johnson & Johnson's performance was bolstered by strong earnings and an increase in full-year revenue guidance, focusing on six priority areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision [3] - The company is entering a new era of accelerated growth and innovation, supported by key growth products and a robust pipeline, reaffirming confidence in its long-term prospects [3]

Group 1 - NVIDIA Corporation is experiencing a decline in stock value despite having a successful meeting, indicating that it is part of a broader downturn in the technology sector [1] - The company's multi-billion-dollar investments are aimed at creating an ecosystem that enhances its importance in software development and artificial intelligence, which is currently not favored in the market [2] - The cyclical nature of the technology industry suggests that while NVIDIA and other tech companies like Google and Meta are currently out of favor, they are expected to recover over time [2] Group 2 - Investors are advised to be cautious with NVIDIA stock, as the current market sentiment is not favorable, and immediate returns are unlikely due to ongoing challenges in the industry [2]

Company Overview - AeroVironment, Inc. (NASDAQ:AVAV) specializes in developing robotic and autonomous systems, including uncrewed aircraft, counter-UAS tools, precision-strike solutions, advanced AI, and autonomy [3] - The company also provides space, cyber, communications, and intelligence systems for defense and commercial applications [3] Recent Developments - AeroVironment announced a deal to acquire BlueHalo for $4.1 billion to leverage its counter-drone technology and satellite capabilities [4] - BlueHalo holds a significant contract with the Pentagon for satellite work, but the stock faced a decline due to news that the contract will be rebid [4] Investment Insights - Jim Cramer expressed caution regarding AeroVironment, highlighting concerns over a contested contract that could negatively impact the stock if not secured [1] - Despite AeroVironment's strong technology, there are questions about the valuation of the BlueHalo acquisition, particularly if the contract is lost [4] - Cramer noted that while AeroVironment is a long-time favorite, current circumstances do not seem favorable for investment [3]